fbpx
Connect with us

MedTech

Nanotechnology in drug delivery market to reach $182.3 billion by 2027

Yehia El Amine

Published

 on

Nanotechnology

While 2020 will always be written off by many as the year that vastly disrupted people’s life, medical researchers may well look back at this year at the tipping point that saw the world place greater emphasis on their work.

While funds poured into COVID-19 vaccinations, medical technology was making a silent rise behind the curtain; and nanotechnology in drug delivery was one of its main champions.

According to UnivDavos Market Insights, the global nanotechnology in drug delivery market is expected to grow at a CAGR of 19.9 percent from 2021-2027 to reach $182.3 billion by 2027.

The global nanotechnology in drug delivery market is experiencing significant growth on account of surging prevalence of cancer, cardiovascular and other diseases. More people die from cardiovascular disease worldwide than from any other source, according to the World Health Organization with over 17.9 million persons succumbing to the disease per year.

Nanotechnology in drug delivery applications occur using designed nanomaterials as well as forming delivery systems from nanoscale molecules such as liposomes. The effects of it would lead to improved ability to deliver drugs that are poorly water soluble, provides site-specific targeting to reduce drug accumulation within healthy tissue, and helps retain the drug in the body long enough for effective treatment.

In 2020, American Heart Association has set a goal of reducing cardiovascular disease and stroke deaths by 20 percent and thus focused on enhancing factors such as physical activity, diet, obesity/overweight, smoking, blood pressure, cholesterol, and blood sugar.

“The rising number of deaths has caused an increased burden among people, which can surge the demand for novel nanotechnology in drug delivery techniques that are more efficient than traditional medicine and therefore is expected to drive the general market to grow,” the UnivDavos report explained.

It also highlighted a major expansion in the transformation of nano-based cancer therapies and diagnostics and different new technologies that are in the pipeline. Nanomedicine and nano delivery systems are being utilized as diagnostic tools or in delivering therapeutic agents to specific targeted sites in a controlled manner wherein materials are used in the nanoscale range.

“Since 1995, nearly 50 nano pharmaceuticals have received FDA approval and are currently available for clinical use. In oncology, over 20 percent of the therapeutic nanoparticles already in clinics or under clinical evaluation have been created. Most FDA-approved therapeutic nanoparticles are currently being designed for the re-formulation of combinations of chemotherapeutic drugs with polymeric nanoparticles,” the report noted. 

The current impact of COVID-19 on global health is enormous, but in addition, the worldwide impact on the economy, employees, and companies is going to be considerable. This global emergency calls for a science and technology response to the COVID-19 pandemic, where advanced solutions during the epidemic are anticipated to be explored by nanotechnology.

A study performed by Leuschner brings a direction in the use of nanotechnology to control the cytokine storm which is amongst few clinical complications of COVID-19. Nanoparticles perform an essential role at different stages of disease pathogenesis, contemplating their inhibition potential in the initial attachment and membrane fusion during viral entry and infected cell protein fusion.

The report by UnivDavos categorized the nanotechnology in drug delivery market in several aspects; by technology, the market is primarily bifurcated into nanoparticles, liposomes, nanocrystals, micelles, and others.

The nanoparticles segment dominated by nanotechnology in drug delivery market and will grow at 19.4 percent CAGR to reach US$ 48.1 billion by the year 2027.

By application, the market is primarily segmented into oncology, cardiovascular/physiology, anti-inflammatory/immunology, neurology, and anti-infective.

Amongst application type, oncology accounted for the largest share and is expected to grow at 20 percent CAGR during the forecast period 2021-2027. In 2019, the oncology segment accounted for a revenue share of almost 36 percent.

The nanotechnology in drug delivery market by geographical segmentation includes North America (the United States, Canada, and Rest of North America), Europe (Germany, United Kingdom, Italy, France, Spain, and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia-Pacific), and the rest of the world.

Based on the study’s estimation, the North America region dominated the market with almost US$ 18.9 billion revenue in 2019. At the same time, the Asia-Pacific region is expected to grow remarkably with a CAGR of 22.5 percent over the forecast period based on the increasing population and modernization of healthcare infrastructure.

Yehia is an investigative journalist and editor with extensive experience in the news industry as well as digital content creation across the board. He strives to bring the human element to his writing.

MedTech

Sleep therapy device raises over $315.38 in crowdfunding

Karim Husami

Published

 on

A UK-designed sleep therapy solution with global ambitions raised over $314.21 in the first week of a Crowdcube crowdfunding campaign.

SleepCogni, a portable device with data support for people suffering from insomnia, has so far attracted funds from 157 different investors in this latest fundraiser that combines venture capital investments and crowdfunding.

The firm’s latest lenders include Chasnay ​​Capital Investments, a new private investment fund founded by three former senior executives from General Electric (GE) Healthcare.

Co-founded by Sheffield-based entrepreneur Richard Mills, who has personally suffered from sleeping disorders, and Dutch chronobiologist and sleep expert, Dr Maan van de Werken, said the device allows users to self-manage their insomnia, a condition which affects one in three people across the world.

“Our successful crowdfund campaign builds on the momentum of last month’s FDA registration and the completion of clinical trials where SleepCogni achieved extraordinary results reducing clinical insomnia in just seven days.”

Reinaldo Garcia from Chasnay Capital Investments added: “We’re excited by our investment into SleepCogni for many reasons: its patented technology and clinically validated solution addresses an unmet need in the global sleep aid market, and the company is backed by an excellent team. As experienced global senior leaders with a proven track record, we can add value in this next exciting stage of the business and help SleepCogni scale on a global level.”

Continue Reading

MedTech

Pfizer vaccine efficacy falls to 84% after 6 months

Hala Turk

Published

 on

Pfizer and BioNTech published on Wednesday new data indicating their COVID-19 vaccine efficacy decline from 96 percent to 84 percent over six months.

These numbers are regarded as a big motivator to the drug makers currently developing a third “booster shot” to target the Indian Delta variant. 

The released data shows that the antibody levels are much higher against the Alpha coronavirus variant and the South African Beta variant, after a third dose.

Based on the figures, the efficacy “declined gradually” as it dropped from 96 percent during the first week to around two months after receiving a second jab. The dose’s effectiveness then plummeted to 83.7 percent four to six months later with an average drop of 6 percent over the last two months.

The findings may be considered by U.S. health authorities in deciding when the pair’s booster shot might be needed.

The data, which involved tests of 23 people, was published by Pfizer and has not been peer reviewed by the scientific community.

The announcement of the data and was released on the day of the company’s earnings call.

During the call, Mikael Dolsten chief scientific officers described the new data on a third dose of vaccine “encouraging.”

“Receiving a third dose more than six months after vaccination, when protection may be beginning to wane, was estimated to potentially boost the neutralizing antibody titers in participants in this study to up to 100 times higher post-dose three compared to pre-dose three,” Dolsten said in a statement.

Despite Pfizer and its German partner BioNTech’s booster shot plans, both Centers for Disease Control and Prevention (CDC) as well as Food and Drug Administration (FDA) released a joint statement highlighting that Americans who have been fully vaccinated do not need a booster shot at this moment in time.

The statement noted that FDA, CDC, and National Institutes of Health (NIH) are engaged in a science-based process to consider whether or when a booster might be necessary.

Continue Reading

MedTech

Google delays return to office, mandates vaccines

Associated Press

Published

 on

Google delays return to office, mandates vaccines

Google is postponing a return to the office for most workers until mid-October and rolling out a policy that will eventually require everyone to be vaccinated once its sprawling campuses are fully reopened.

The more highly contagious delta variant of the coronavirus is driving a dramatic spike in COVID-19 cases and hospitalizations. Google’s Wednesday announcement was shortly followed by Facebook, which also said it will make vaccines mandatory for U.S. employees who work in offices. Exceptions will be made for medical and other reasons.

In an email sent to Google’s more than 130,000 employees worldwide, CEO Sundar Pichai said the company is now aiming to have most of its workforce back to its offices beginning Oct. 18 instead of its previous target date of Sept. 1.

The decision also affects tens of thousands of contractors who Google intends to continue to pay while access to its campuses remains limited.

“This extension will allow us time to ramp back into work while providing flexibility for those who need it,” Pichai wrote.

And Pichai disclosed that once offices are fully reopened, everyone working there will have to be vaccinated. The requirement will be first imposed at Google’s Mountain View, California, headquarters and other U.S. offices, before being extended to the more than 40 other countries where Google operates.

“This is the stuff that needs to be done, because otherwise we are endangering workers and their families,” said Dr. Leana Wen, a public health professor at George Washington University and a former health commissioner for the city of Baltimore. “It is not fair to parents to be expected to come back to work and sit shoulder-to-shoulder with unvaccinated people who could be carrying a potentially deadly virus.”

Because children under the age of 12 aren’t currently eligible to be vaccinated, parents can bring the virus home to them from the office if they are around unvaccinated colleagues, Wen said.

Various government agencies already have announced demands for all their employees to be vaccinated, but the corporate world so far has been taking a more measured approach, even though most lawyers believe the mandates are legal.

Delta and United airlines are requiring new employees to show proof of vaccination. Goldman Sachs and Morgan Stanley are requiring their employees to disclose their vaccination status, but are not requiring staffers to be vaccinated.

Less than 10% of employers have said they intend to require all employees to be vaccinated, based on periodic surveys by the research firm Gartner.

While other major technology companies may follow suit now that Google and Facebook have taken stands on vaccines, employers in other industries still may be reluctant, predicted Brian Kropp, chief of research for Gartner’s human resources practice.

“Google is seen as being such a different kind of company that I think it’s going to take one or two more big employers to do something similar in terms of becoming a game changer,” Kropp said.

Google’s vaccine mandate will be adjusted to adhere to the laws and regulations of each location, Pichai wrote, and exceptions will be made for medical and other “protected” reasons.

“Getting vaccinated is one of the most important ways to keep ourselves and our communities healthy in the months ahead,” Pichai explained.

Google’s decision to require employees working in the office to be vaccinated comes on the heels of similar moves affecting hundreds of thousands government workers in California and New York as part of stepped-up measures to fight the delta variant. President Joe Biden also is considering mandating all federal government workers be vaccinated.

The rapid rise in cases during the past month has prompted more public health officials to urge stricter measures to help overcome vaccine skepticism and misinformation.

The vaccine requirement rolling out in California next month covers more than 240,000 government employees. The city and county of San Francisco is also requiring its roughly 35,000 workers to be vaccinated or risk disciplinary action after the Food and Drug Administration approves one of the vaccines now being distributed under an emergency order.

It’s unclear how many of Google’s workers still haven’t been vaccinated. In his email, Pichai described the vaccination rate at the company as high.

Google’s decision to extend its remote-work follows a similar move by another technology powerhouse, Apple, which recently moved its return-to-office plans from September to October, too.

The delays by Apple and Google could influence other major employers to take similar precautions, given that the technology industry has been at the forefront of the shift to remote work triggered by the spread of the novel coronavirus.

Even before the World Health Organization declared a pandemic in March 2020, Google, Apple and many other prominent tech firms had been telling their employees to work from home. This marks the third time Google has pushed back the date for fully reopening its offices.

Google’s vaccine requirement also could embolden other employers to issue similar mandates to guard against outbreaks and minimize the need to wear masks in the office.

While most companies are planning to bring back their workers at least a few days a week, others in the tech industry have decided to let employees do their jobs from remote locations permanently.


SAN RAMON, Calif. (AP)

Continue Reading

Trending